GlassScriptPhysician profile
Yuan Yao
NPI 1417301375
$10,109.30
in general payments reported to CMS, 2019-2025
28 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $652 · 2021: $1,541 · 2022: $1,811 · 2023: $1,994 · 2024: $1,821 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,903.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,321.66 | 2020-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,044.63 | 2020-2024 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $945.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $908.28 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $771.11 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $735.99 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $733.30 | 2022-2025 | |
| Ibsa Pharma INC. | $699.48 | 2021-2024 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $628.99 | 2021-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $561.58 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $413.33 | 2023-2025 | |
| Esperion Therapeutics, INC. | $289.95 | 2021-2025 | Nexletol |
| Abbvie INC. | $138.32 | 2020-2021 | |
| Lilly USA, LLC | $131.83 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Merck Sharp & Dohme LLC | $127.40 | 2019-2025 | Enflonsia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $125.33 | 2021-2025 | Arikayce, Brinsupri |
| Agios Pharmaceuticals, INC. | $104.98 | 2024-2025 | Pyrukynd |
| Xeris Pharmaceuticals, INC. | $100.22 | 2024-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Shield Therapeutics INC | $58.06 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $49.36 | 2024-2025 | Zoryve |
| Mylan Specialty L.P. | $42.34 | 2021-2024 | Yupelri |
| Genentech USA, INC. | $40.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2021-2022 | |
| Viatris Specialty LLC | $26.84 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2021 | |
| Verona Pharma, INC. | $18.75 | 2025 | Ohtuvayre |
| Phadia US INC. | $15.70 | 2023 | Immunocap |
| Hikma Pharmaceuticals USA | $15.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuan Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.